BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 35802774)

  • 1. Dysregulated ceramides metabolism via PTPN11 exposes a metabolic vulnerability to breast cancer metastasis.
    Qiao S; Wang T; Wang H
    Med Oncol; 2023 Sep; 40(11):310. PubMed ID: 37773553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.
    Liu P; Liu Z; Luo Q; Fu Q; Zhang X; Yu P; Zhou S; Wang Y; Zhang J; Chen S; Zhang H; Zhu Q; Qin T
    Sci Rep; 2023 Aug; 13(1):13898. PubMed ID: 37626178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLMO2 is a potential prognostic and immunological biomarker in human pan-cancer.
    Liu X; Yuan R; Peng J; Xu A; Nie X; Tang R; Li G
    Sci Rep; 2024 Jan; 14(1):1070. PubMed ID: 38212657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the clinical characteristics and prognosis of adult
    Sheng L; Liu Y; Zhu Y; Zhou J; Hua H
    Open Med (Wars); 2023; 18(1):20230830. PubMed ID: 38025540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.
    Yuan L; Bing Z; Yan P; Li R; Wang C; Sun X; Yang J; Shi X; Zhang Y; Yang K
    Gene; 2019 Oct; 716():144025. PubMed ID: 31394177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pan-cancer analysis confirms PTPN11's potential as a prognostic and immunological biomarker.
    Cao Y; Duan H; Su A; Xu L; Lai B
    Aging (Albany NY); 2022 Jul; 14(13):5590-5610. PubMed ID: 35802774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
    Toral KJ; Wuenschel MA; Black EP
    PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 12. Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization.
    Xu Z; Guo C; Ye Q; Shi Y; Sun Y; Zhang J; Huang J; Huang Y; Zeng C; Zhang X; Ke Y; Cheng H
    Nat Commun; 2021 Nov; 12(1):6310. PubMed ID: 34728626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
    Song Y; Zhao M; Zhang H; Yu B
    Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
    CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.